The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
80 jobs Number of planned job losses
Announcement Date
24 November 2021
Employment effect (start)
1 January 2022
Foreseen end date
31 March 2022
Description
Centogene, a German company specialised in diagnostics and research of rare diseases, will be cutting approximately 80 jobs at its site in Rostock. According to the company’s third quarter report, Centogene will phase out its non-core COVID-19 testing services by early 2022 (no exact date available) which will result in the loss of 80 employees out of the 530 people currently employed at the Rostock site.
As of now, there is no information on a social plan available.
Centogene is a global biotechnology company founded in Rostock, Germany with further offices in Germany as well as in US.
Eurofound (2021), Centogene, Internal restructuring in Germany, factsheet number 105864, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/105864.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
